About Obatala Sciences
Obatala Sciences is a company based in New Orleans (United States) founded in 2017 by Xiying Wu. Obatala Sciences has raised $3.54 million across 3 funding rounds from investors including Ochsner, HHS and Elevate Capital. The company has 10 employees. Obatala Sciences offers products and services including ObaCell® ASC Fat-on-a-Chip Kit, ObaGel®, and Human Adipose-Derived Stem Cells. Obatala Sciences operates in a competitive market with competitors including BioLife Solutions, Emulate, CN Bio, RoosterBio and Shanghai Doning Biotechnology, among others.
- Headquarter New Orleans, United States
- Employees 10
- Founders Xiying Wu
- SectorsHealthcare
- Phone•••• ••••
- Website obatalasciences.com
- Social LinkedIn
- Legal Name Obatala Sciences, Inc
- Total Equity Funding$3.54M (USD)
in 3 rounds
- Latest Funding Round$3M (USD), Series A
Oct 2022
- InvestorsOchsner
& 6 more
- Employee Count10
Products & Services of Obatala Sciences
Obatala Sciences offers a comprehensive portfolio of products and services, including ObaCell® ASC Fat-on-a-Chip Kit, ObaGel®, and Human Adipose-Derived Stem Cells.
Kit for modeling adipose tissue in pre-clinical drug development research.
Human-derived hydrogel for stem cell expansion and tissue engineering.
Stem cells for use in biomedical research and disease modeling.
Funding Insights of Obatala Sciences
Obatala Sciences has successfully raised a total of $3.54M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.54M
- Total Rounds 3
- Last Round Series A — $3M
- First Round $535,000
(Oct 2020)
- Investors Count 7
All 3 funding rounds of Obatala Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | $3M | Series A | – | être, Ochsner Lafayette General | |
| Sep 2022 | $450,702 | Grant | – | – | |
| Oct 2020 | $535,000 | Seed | – | Ochsner | – |
7 investors in total: 7 institutional.
Investors in Obatala Sciences
Obatala Sciences has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Ochsner, HHS and Elevate Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on underserved entrepreneurs is provided. | – | elevate.vc | Hillsboro, United States | |
Venture capital funding is provided by être Venture Capital. | – | etrevc.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Healthcare services, research, education, and community support are provided. | 1942 | ochsner.org | United States | |
- | – | ochsnerlg.org | - | |
- | – | bensoncp.com | - | |
- | – | hackett-group.com | - |
Investor details for Obatala Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Obatala Sciences
12 people are tracked at Obatala Sciences (5 in leadership, 5 in board & advisors, 2 in team); the tracked headcount is 10.
| Name | Role | Group |
|---|---|---|
Xiying Wu | Co-Founder | Leadership |
Trivia Frazier | CEO | Leadership |
Jeffrey Gimble | Chief Medical Officer, Board Member & Co-Founder | Leadership |
Cecilia Sanchez | Chief Scientific Officer & VP of R&D | Leadership |
Katie Hamel | Director of Technical Writing | Leadership |
Shafin Khan | Advisor | Board & advisors |
Jennifer Kuan | Advisor | Board & advisors |
Frank Greenway III | Advisor | Board & advisors |
Ken Eilertsen | Advisor | Board & advisors |
Elizabeth Floyd | Advisor | Board & advisors |
Kevin Hicok | Regulatory Consultant | Team |
Jordan Robinson | Tissue Engineering Scientist | Team |
Complete people profiles for Obatala Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Obatala Sciences
3 dated milestones of Obatala Sciences across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Obatala Sciences is founded.
- Funding First funding round of $535K.
- Funding Latest funding round, Series A, of $3.0M.
Competitors of Obatala Sciences
Obatala Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioLife Solutions, Emulate, CN Bio, RoosterBio and Shanghai Doning Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biolifesolutions.com | 1987 | Bothell, United States | – | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | |
| emulatebio.com | 2013 | Boston, United States | $204.49M | 93 | Developer of in vitro models for drug development | |
| cn-bio.com | 2009 | Cambridge, United Kingdom | $44.78M | 33 | Organ-on-a-chip platforms are developed for drug discovery applications. | |
| roosterbio.com | 2012 | Frederick, United States | $38.41M | 69 | Developer of human mesenchymal stem cells and extracellular vesicles | |
| duoningbio.com | 2005 | Shanghai, China | $14.88M | – | Serum-free cell culture media is supplied to biopharmaceutical industries. | |
| arunabio.com | 2017 | Athens, United States | $38.51M | – | Neural exosome platform is developed for neurodegenerative disease therapeutics. | |
| axosim.com | 2014 | New Orleans, United States | $6.78M | 27 | Nerve-on-a-chip technology is advanced by AxoSim for drug development improvement. | |
| biotangents.co.uk | 2015 | Edinburgh, United Kingdom | $5.62M | 13 | Veterinary diagnostics products are developed for bovine viral diarrhea testing. | |
| mimetas.com | 2013 | Leiden, Netherlands | $28.9M | – | Microfluidics-based organ-on-a-chip models for drug evaluation are developed. | |
| polyplus-transfection.com | 2001 | Illkirch Graffenstaden, France | $3.23M | – | Transfection Solutions for Healthcare and Life Sciences organizations |
Detailed competitors of Obatala Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Obatala Sciences
The website of Obatala Sciences (obatalasciences.com) receives about 4.8K visits a month.
- Monthly visits4.8K
▲ 110.7% vs previous month
Latest news on Obatala Sciences
Complete news archive for Obatala Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Obatala Sciences
10 companies that operate in the same segment as Obatala Sciences (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Obatala Sciences
Obatala Sciences was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Obatala Sciences is headquartered in New Orleans, United States. It is registered at New Orleans, Louisiana, United States.
Trivia Frazier is the current CEO of Obatala Sciences.
Obatala Sciences is a funded company, having raised a total of $3.54M across 3 funding rounds to date. The company's 1st funding round was a Seed of $535K, raised on Oct 2020.
Obatala Sciences has 10 employees.
Provider of research enabling products and services to research centers. The platform offers multiple services such as adipose tissue-derived stromal stem cells, human adult primary cell, 3D discovery tools such as ObaGel and ObaCell among others. The platform also offers medial and culture reagents such as OsteoQual.
Obatala Sciences's top competitors include Emulate, CN Bio and RoosterBio.
Obatala Sciences offers ObaCell® ASC Fat-on-a-Chip Kit, ObaGel®, and Human Adipose-Derived Stem Cells.
Obatala Sciences has 7 investors. Key investors include Ochsner, HHS, Elevate Capital, être Venture Capital, and Ochsner Lafayette General.
Obatala Sciences operates through Obatala Sciences, Inc.